Best African American Response to Asthma Drugs

Exclusion Criteria

• •1. Medical contraindication to LABA or history of adverse reactions to ICS or LABA preparations or any of their ingredients.
• •2. Current or prior use of medications known to significantly interact with corticosteroid disposition within the two-week period preceding enrollment.
• •3. Unwilling to provide a blood sample for DNA extraction and genetic analysis.
• •4. Major medical problems prohibiting study participation, i.e. presence of chronic or active lung disease other than asthma or history of unstable significant medical illness other than asthma, including thyroid disease, diabetes mellitus, Cushing's disease, Addison's disease, hepatic disease, or concurrent medical problems that could require oral corticosteroids during the study or that would place the participant at increased risk.
• •5. Systemic corticosteroid treatment for any condition within 4 weeks of enrollment or more than five courses of systemic corticosteroids in the past year.
• •6. History of a life-threatening asthma exacerbation requiring intubation, mechanical ventilation, or resulting in a hypoxic seizure within the last 2 years.
• •7. History of a respiratory tract infection within 4 weeks of enrollment.
• •8. If a female of child-bearing potential, failure to practice abstinence or use an acceptable birth control method.
• •9. Pregnancy or lactation or planning to get pregnant during the course of the trial.
• •10. Receiving hyposensitization therapy other than an established maintenance regimen defined as a continuous regimen for ≥ 3 months prior to enrollment.
• •11. Participation in an intervention trial or use of investigative drugs in the past 30 days or plans to enroll in such a trial during the study.